Mens Health Medicines

Stretching exercises may be more effective at reducing the risk of preeclampsia than walking is for pregnant women who have already experienced the condition and who do not follow a workout routine, according to researchers at the University of North Carolina at Chapel Hill School of Nursing.
Preeclampsia, or pregnancy-induced hypertension, is a condition that affects up to 8 percent of pregnancies every year and is among the leading causes of maternal and fetal illness and death worldwide.
The finding is contrary to existing studies and literature that suggest that rigorous exercise is the most effective way to reduce the risk of preeclampsia, said SeonAe Yeo, Ph.D., an associate professor with a specialty in women’s health at the UNC School of Nursing and the study’s lead researcher.
Yeo will present the findings Thursday (May 29) at the annual meeting of the American College of Sports Medicine in Indianapolis, Ind. The results will be published in the spring issue of the journal Hypertension in Pregnancy.
Preeclampsia is characterized by a marked increase in blood pressure during pregnancy and may be accompanied by swelling and kidney problems. It is diagnosed when blood pressure readings taken twice in six hours read 140/90 or higher.
"These results seemingly contradict the conventional wisdom that walking is the best protection pregnant women have against developing preeclampsia," Yeo said. "But for women who were not physically active before becoming pregnant and who have experienced preeclampsia with a previous pregnancy, that might not be the case."
From November 2001 to July 2006, 79 women with a previous preeclampsia diagnosis and a sedentary lifestyle participated in this National Institute of Nursing Research-funded study. Women were randomly assigned to either the walking group (41 women) or the stretching group (38 women) during the 18th week of pregnancy.
The walking group was asked to exercise for 40 minutes five times a week at moderate intensity, following the program recommended by the Surgeon General and the American College of Obstetrics and Gynecology. Stretchers were also asked to perform slow, non-aerobic muscle movements with a 40-minute video fives times a week. Frequency and duration of exercise decreased in both groups as the pregnancy progressed.
At the end of pregnancy, almost 15 percent of women in the walking group had developed preeclampsia. Less than 5 percent of the stretching group developed the condition. While the incidence of preeclampsia in the walking group was similar to that reported in high-risk pregnancies, the frequency among the stretching group was similar to rates seen among the general population.
"Clearly, walking does not have a harmful effect during pregnancy," Yeo said. "But for women who are at high risk for preeclampsia, our results may suggest that stretching exercises may have a protective effect against the condition."
Stretching could provide protection against preeclampsia because stretchers produced more transferrin than walkers did, Yeo said. Transferrin is a plasma protein that transports iron through the blood and protects against oxidative stress on the body.
Yeo said these results could help prenatal care providers recommend different exercise plans based on an individual pregnant woman’s needs and abilities. Following an active exercise plan is good, she said, but only if a pregnant woman is truly able to do it. For some who already have a risk of preeclampsia, stretching might be a better option.
comprare generico cialis soft Co-authors of the study include Sandra Davidge, Ph.D., University of Alberta; David L. Ronis, Ph.D., University of Michigan School of Nursing and Veterans Administration Hospital in Ann Arbor, Mich.; Cathy L. Antonakos, Ph.D., University of Michigan School of Nursing; Robert Hayashi, M.D., University of Michigan School of Medicine; and Sharon O’Leary, M.D., St. Joseph Mercy Health Systems, Ypsilanti, Mich.
University of North Carolina at Chapel Hill
210 Pittsboro St. Campus Box 6210
Chapel Hill, NC 27514
United States

comprare il viagra soft senza ricetta | generico levitra in linea comrare | comprare cialis mastercard

European Society of
Hypertension — Booth # 21, Hall 15.1 — InterCure Ltd., a medical device
company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR),
announced the findings of new studies and analysis highlighting RESPeRATE
– the only medical device cleared by the FDA and CE-approved for the
treatment of hypertension. Five posters will be presented at the European
Society of Hypertension meeting (ESH) in Berlin beginning June 14, 2008.
Two of the five posters focus on RESPeRATE’s effect on blood pressure as
measured by 24-hour ambulatory blood pressure monitoring. Three of the
posters also present new findings in the emerging field of obtaining
vascular risk parameters from blood pressure measurements. The fifth poster
demonstrates the benefits of RESPeRATE in patients with chronic heart
failure.
"InterCure is making great strides within the European marketplace and
has received a tremendous response from both the scientific and consumer
communities," says Erez Gavish, president and CEO of InterCure. "The
continued clinical interest is producing a constant drumbeat of validation
for RESPeRATE, paving the path for the successful charge into retail
outlets in Europe and the U.S. and building on the more than 100,000
hypertension sufferers who have already adopted RESPeRATE as a treatment
for their hypertension."
Results of the findings related to RESPeRATE are being presented as
posters at ESH and are as follows:
– PS26/WED/05 — A study performed in Turkey, led by Prof. Erdine,
Department of Cardiology, Istanbul University, demonstrated that the
RESPeRATE device provides daytime and nighttime blood pressure
reductions as measured by 24-hour ambulatory monitoring. The study
also demonstrated that patients were compliant with the device and that
no adverse side effects were reported.
– PS33/THU/01 — Pooled results from two separate studies led by Profs.
Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory
blood pressure monitoring demonstrated that RESPeRATE benefits
uncontrolled-hypertension sufferers. The analysis demonstrated a
clinically significant blood pressure reduction throughout both daytime
and nighttime. RESPeRATE was also found to independently reduce high
values of a risk-associated arterial property (S-D slope/AASI) derived
from the relationship between systolic and diastolic pressures.
– PS34/MON/08 — Data analysis led by Dr. Benjamin Gavish, chief
scientific officer, InterCure, Ltd., of a study performed in Italy,
conducted by Prof. Gianfranco Parati, explored, for the first time, the
linear relationships between systolic and diastolic blood pressure from
beat-to-beat measurements. The derived risk-related parameters (S-D
slope and AASI) are acutely influenced by breathing patterns and neck
suction.
– PS34/MON/18 — An Israeli study, conducted by Dr. Iddo Ben-Dov and
Prof. generishe cialis pillen Ohne Rezept Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin
Gavish, concluded that the ratio of systolic to diastolic blood
pressure variability is shown to be a blood pressure-independent
predictor of mortality, associated with the linear relationship between
systolic and diastolic pressures.
– PS18/WED/58 — An Italian, randomized controlled study, led by Prof. G.
Parati from the University of Milan-Bicocca concluded that device-
guided paced breathing at home is feasible and improves prognostically
relevant clinical and instrumental parameters in heart failure
patients. It is recommended as an additional long-term treatment
program for these patients.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42
billion hypertension industry with the world’s first FDA-cleared, OTC blood
pressure treatment device, RESPeRATE(R) (). In a
market where seven out of 10 hypertensives are NOT controlled despite the
availability of more than 100 blood pressure medications, RESPeRATE
provides an effective non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and
has secured regulatory clearance in most key international markets. Ten
separate clinical studies have proven the device’s efficacy and safety, and
RESPeRATE is now featured in more than 20 popular and professional text
books.
With more than 100,000 units sold, thousands of supportive clinicians
worldwide and one of the world’s most popular hypertension websites,
InterCure is now introducing RESPeRATE into retail pharmacies to increase
access to hypertension sufferers.
InterCure has an exciting product pipeline based on its
broadly-patented "Device-Guided Breathing" technology platform. This
technology enables a systematic reduction in sympathetic outflow of the
autonomic nervous system, one of the key underlying causes of
cardiovascular disease, insomnia and several other medical conditions.
Forward-Looking Statements
This news release may contain forward-looking statements that are based
on the Company’s current beliefs and assumptions and on information
currently available to its management. Forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause the
Company’s actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements. As a result of these risks,
uncertainties and other factors, readers are cautioned not to place undue
reliance on any forward-looking statements included in this press release.
These forward- looking statements represent beliefs and assumptions only as
of the date of this news release, and the Company assumes no obligation to
update these forward-looking statements publicly, even if new information
becomes available in the future.
InterCure, Inc.

kaufen viagra Ohne Rezept | Kaufen generishe viagra soft | generishe levitra online kaufen mastercard

A study based at The University of Texas Health Science Center at Houston provides added justification that a thiazide-type diuretic is the best first-choice drug for hypertensive patients. The findings, published in the American Heart Association’s Circulation, Volume 117, Issue 20, evaluate the results of a previous trial coordinated by researchers at The University of Texas School of Public Health, along with other recent studies.
According to the American Heart Association, about one in three U.S. adults has high blood pressure. Uncontrolled high blood pressure can lead to stroke, heart attack, heart failure or kidney failure. A joint national committee (JNC) on the prevention, detection and evaluation of high blood pressure meets on a regular basis to summarize suggested guidelines for doctors on treating hypertension based on medical research. acheter viagra soft mastercard The study, titled "Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension," analyzes the guidelines of the committee based on previous and recent research.
The findings of the JNC are based on information stemming from a landmark investigation at the UT School of Public Health, which in 2002 established that diuretics were "as good or better" than three other classes of medications for high blood pressure. The original investigation was called ALLHAT - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
"We found that further analyses of the original ALLHAT trial and information from more recent studies confirmed the original findings that diuretics are the preferred choice for antihypertensive therapy, alone or in combination with other drugs," said Barry Davis, M.D., Ph.D., professor of biostatistics and the director of the Coordinating Center for Clinical Trials at the UT School of Public Health.
"Five years after the ALLHAT results were published, the JNC recommendation still holds," added Davis, who co-authored the study with Jeffrey A. Cutler, M.D., MPH, a consultant to the National Heart, Lung and Blood Institute (NHLBI).
The most recent committee highlighted ALLHAT’s findings in the revision of its guidelines, meaning the information will now be used for practical treatments. The committee states that when compared to calcium channel blockers, ACE inhibitors and alpha blockers, thiazide-type diuretics are better first-line drug treatments for hypertensive patients. The diuretics excelled in controlling blood pressure, preventing cardiovascular events, are well tolerated by patients and are relatively inexpensive.
Original ALLHAT findings appear in two articles in a 2002 issue of The Journal of the American Medical Association (JAMA). The project consisted of two clinical trials: one compared a diuretic with newer and more expensive antihypertensive drugs to start blood pressure-lowering treatment to ascertain which was best at preventing cardiovascular outcomes; the other compared a statin drug to usual care in lowering cholesterol levels to determine if treatment would lower the occurrence of deaths over the study period. The articles and details of the study and its findings can be found on the study’s web site,
University of Texas Health Science Center at Houston
7000 Fannin St., #1200
Houston, TX 77030
United States

acheter viagra bon marche | generique viagra soft en ligne acheter | Generique cialis soft pilules bon marche

Having intercourse more often may help prevent the development of erectile dysfunction (ED). A study published in the July 2008 issue of The American Journal of Medicine reports that researchers have found that men who had intercourse more often were less likely to develop ED.
Analyzing a five-year study of 989 men aged 55 to 75 years from Pirkanmaa, Finland, the investigators observed that men reporting intercourse less than once per week at baseline had twice the incidence of erectile dysfunction compared with those reporting intercourse once per week. Further, the risk of erectile dysfunction was inversely related to the frequency of intercourse.
Other factors that may affect the incidence of ED, such as age, chronic medical conditions (diabetes, heart disease, hypertension, cerebrovascular disease and depression), body mass index and smoking were included in the analysis of the data.
Erectile dysfunction incidence was 79 cases per 1000 in men who had reported sexual intercourse less than once per week, dropping to 32 cases per 1000 in men reporting intercourse once per week and falling further to 16 per 1000 in those reporting intercourse 3 or more times per week.
In addition, the frequency of morning erections predicted the development of complete erectile dysfunction, with an approximate 2.5-fold risk among those with less than 1 morning erection per week compared with 2 to 3 morning erections per week
Writing in the article, Juha Koskim?¤ki, MD, PhD, Tampere University Hospital, Department of Urology, Tampere, Finland, states; "Regular intercourse has an important role in preserving erectile function among elderly men, whereas morning erection does not exert a similar effect. Continued sexual activity decreases the incidence of erectile dysfunction in direct proportion to coital frequency."
The study clearly indicates that regular intercourse protects men from the development of erectile dysfunction, which may, in turn, impact general health and quality of life. The investigators advise clinicians to support the sexual activity of their patients.
"Regular Intercourse Protects Against Erectile Dysfunction: Tampere Aging Male Urologic Study"
Juha Koskimaki, MD, PhD, Rahman Shiri, MD, PhD, Teuvo Tammela, MD, PhD, Jukka Hakkinen, MD, PhD, Matti Hakama, ScD, and Anssi Auvinen, MD, PhD.
The American Journal of Medicine, Volume 121, Issue 7 (July 2008) published by Elsevier.
ABOUT THE AMERICAN JOURNAL OF MEDICINE
The American Journal of Medicine, known as the "Green Journal," is one of the oldest and most prestigious general internal medicine journals published in the United States. It is ranked 11th out of 100 General and Internal Medicine titles according to the 2007 Journal Citation Reports© published byThomsonReuters. www.amjmed.com.
Kaufen generishe levitra AJM, the official journal of The Association of Professors of Medicine, a group comprised of chairs of departments of internal medicine at 125-plus U.S. medical schools, publishes peer-reviewed, original scientific studies that have direct clinical significance. The information contained in this article in The American Journal of Medicine is not a substitute for medical advice or treatment, and the Journal recommends consultation with your physician or healthcare professional. AJM is published by Elsevier.
ABOUT ELSEVIER
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (www.sciencedirect.com), MD Consult (www.mdconsult.com), Scopus (www.info.scopus.com), bibliographic databases, and online reference works.
Elsevier (www.elsevier.com) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (www.reedelsevier.com), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
kaufen cialis Ohne Rezept | generishe levitra online kaufen mastercard | generishe viagra soft online kaufen mastercard